The likelihood of developing BrM is contingent upon the subtype, with a heightened occurrence in individuals with human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancer [1]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.